Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorAnderson, Heather
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2009-07-22T10:03:06Z
dc.date.available2009-07-22T10:03:06Z
dc.date.issued2005-07-01
dc.identifier.citationSequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. 2005, 11 (13 Pt 2):5051s-5056s Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid16000613
dc.identifier.doi10.1158/1078-0432.CCR-05-9004
dc.identifier.urihttp://hdl.handle.net/10541/74915
dc.description.abstractCombined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCisplatin
dc.subject.meshCombined Modality Therapy
dc.subject.meshDose Fractionation
dc.subject.meshDrug Administration Schedule
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshNeoadjuvant Therapy
dc.titleSequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 9BX, United Kingdom. nick.thatcher@christie-tr.nwest.nhs.uken
dc.identifier.journalClinical Cancer Researchen
html.description.abstractCombined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.


This item appears in the following Collection(s)

Show simple item record